Yang Ming-Fang, Lou Yuan-Lei, Liu Si-Sun, Wang Shan-Shan, Yin Chun-Hua, Cheng Xiao-Hua, Huang Ou-Ping
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Institute of Urology, Nanchang University, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
J Cancer. 2018 Jan 1;9(2):304-309. doi: 10.7150/jca.22004. eCollection 2018.
Recent studies have shown a close correlation between Capn4 expression and the prognosis of patients with solid tumors. This study aimed to investigate clinical role of Capn4 in ovarian cancer. The expression of Capn4 in 113 ovarian cancer and 35 non-tumor tissue samples were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Capn4 expression was significantly upregulated in ovarian cancer tissues compared with non-tumor tissues (p < 0.01), and was positively correlated to FIGO stage, tumor grade and distant metastasis of ovarian cancer. Kaplan-Meier analysis indicated that patients with high Capn4 expression had shorter overall survival (HR = 1.929, 95%CI: 1.210-3.077, P= 0.006) and progress-free survival (PFS) (HR = 2.043, 95%CI: 1.276-3.271, P= 0.003). Moreover, univariate Cox regression analysis demonstrated that Capn4 overexpression was an unfavorable prognostic factor for ovarian cancer (HR = 2.819, 95%CI: 1.365-3.645, P = 0.003). After the adjustment with age, histological type and tumor size, multivariate Cox regression analysis showed that Capn4 expression level (HR = 2.157,95%CI: 1.091-3.138, P = 0.014), distant metastasis (HR = 1.576, 95%CI: 1.025-3.012, P = 0.028), tumor grade (HR = 1.408, 95%CI: 0.687-2.884, P = 0.037), and FIGO stage (HR = 1.791, 95%CI: 1.016-3.158, P=0.036) were independent poor prognostic indicators for ovarian cancer. In conclusion, Capn4 has the potential as a new prognostic marker for patients with ovarian cancer.
近期研究表明，组织蛋白酶N4（Capn4）表达与实体瘤患者的预后密切相关。本研究旨在探讨Capn4在卵巢癌中的临床作用。采用定量实时聚合酶链反应（qRT-PCR）检测113例卵巢癌组织和35例非肿瘤组织样本中Capn4的表达。与非肿瘤组织相比，Capn4在卵巢癌组织中的表达显著上调（p<0.01），且与卵巢癌的国际妇产科联盟（FIGO）分期、肿瘤分级及远处转移呈正相关。Kaplan-Meier分析表明，Capn4高表达患者的总生存期（HR=1.929，95%CI：1.210-3.077，P=0.006）和无进展生存期（PFS）较短（HR=2.043，95%CI：1.276-3.271，P=0.003）。此外，单因素Cox回归分析显示，Capn4过表达是卵巢癌的不良预后因素（HR=2.819，95%CI：1.365-3.645，P=0.003）。在对年龄、组织学类型和肿瘤大小进行校正后，多因素Cox回归分析显示，Capn4表达水平（HR=2.157，95%CI：1.091-3.138，P=0.014）、远处转移（HR=1.576，95%CI：1.025-3.012，P=0.028）、肿瘤分级（HR=1.408，95%CI：0.687-2.884，P=0.037）和FIGO分期（HR=1.791，95%CI：1.016-3.158，P=0.036）是卵巢癌独立的不良预后指标。总之，Capn4有可能成为卵巢癌患者新的预后标志物。
